Verapamil is named as an intervention in 4 current clinical trials in our France, Sweden, Denmark and Egypt registers. 3 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Centre Hospitalier Universitaire de Nice (1). The most-studied condition is Cluster Headache. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
NCT05569382 · ClinicalTrials.gov ↗ · Non-obstructive Hypertrophic Cardiomyopathy
|
Phase 4 | Recruiting | Morten Steen Kvistholm Jensen | Denmark |
|
Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
NCT07804849 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus
|
Phase 2/3 | Recruiting | Ain Shams University | Egypt |
|
A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil
NCT07199946 · ClinicalTrials.gov ↗ · Type 1 Diabetes
|
Phase 1/2 | Recruiting | Johnny Ludvigsson | Sweden |
|
Atrioventricular Block and Cluster Headache (SEVA)
NCT04406259 · ClinicalTrials.gov ↗ · Cluster Headache
|
Phase 4 | Active, closed | Centre Hospitalier Universitaire de Nice | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Verapamil. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study
2025-524318-27-00 · Immune System Diseases
|
Phase 2 | Authorised | Assistance Publique Hopitaux De Paris | France |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
6 single-substance products containing Verapamil on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Centre Hospitalier Universitaire de Nice | 1 |
| Johnny Ludvigsson | 1 |
| Morten Steen Kvistholm Jensen | 1 |
| Ain Shams University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 1 | 0 |
| Clinical trials in Sweden | 1 | 1 |
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
4 current trials in our France, Sweden, Denmark and Egypt registers name Verapamil as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 1 with sites in Sweden, 1 with sites in Denmark and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Centre Hospitalier Universitaire de Nice (1), Johnny Ludvigsson (1), Morten Steen Kvistholm Jensen (1) and Ain Shams University (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 6 single-substance products containing Verapamil, for example Isoptin 2.5 mg/ml Solution for Injection or Infusion (Viatris Healthcare Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 2 entries for Verapamil: US FDA: resolved; 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Verapamil works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Verapamil works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Verapamil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.